Drug profile · INN
clonazepam
PAXAM 0.5
clonazepam (PAXAM 0.5) is a gaba-a receptor; anion channel positive allosteric modulator. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — clonazepam
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 4
- Data quality
- 0.89
Quick answer
clonazepam (PAXAM 0.5) is a gaba-a receptor; anion channel positive allosteric modulator. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
GABA-A receptor; anion channel positive allosteric modulator
Primary target: GABA-A receptor; anion channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is clonazepam?
clonazepam (PAXAM 0.5) is a gaba-a receptor; anion channel positive allosteric modulator. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for clonazepam?
PAXAM 0.5 is a marketed brand name for clonazepam. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of clonazepam?
clonazepam has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.